Preclinical studies and observational findings in KTRs suggest that the mTOR inhibitor sirolimus may enable enhanced immunological responses to COVID-19 vaccination, as compared to standard of care immunosuppression which includes mycophenolate. Here, MTOR is linked to COVID-19.